Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.16
CORT's Cash to Debt is ranked lower than
77% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. CORT: 1.16 )
Ranked among companies with meaningful Cash to Debt only.
CORT' s 10-Year Cash to Debt Range
Min: 0.72  Med: 1190.67 Max: No Debt
Current: 1.16
Equity to Asset 0.22
CORT's Equity to Asset is ranked lower than
89% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CORT: 0.22 )
Ranked among companies with meaningful Equity to Asset only.
CORT' s 10-Year Equity to Asset Range
Min: -0.1  Med: 0.64 Max: 0.89
Current: 0.22
-0.1
0.89
F-Score: 3
Z-Score: -1.36
M-Score: -1.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -58.27
CORT's Operating margin (%) is ranked higher than
52% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. CORT: -58.27 )
Ranked among companies with meaningful Operating margin (%) only.
CORT' s 10-Year Operating margin (%) Range
Min: -69827.59  Med: -2540.46 Max: -104.02
Current: -58.27
-69827.59
-104.02
Net-margin (%) -69.10
CORT's Net-margin (%) is ranked higher than
50% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. CORT: -69.10 )
Ranked among companies with meaningful Net-margin (%) only.
CORT' s 10-Year Net-margin (%) Range
Min: -69537.93  Med: -2401.04 Max: -118.2
Current: -69.1
-69537.93
-118.2
ROE (%) -596.12
CORT's ROE (%) is ranked lower than
97% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. CORT: -596.12 )
Ranked among companies with meaningful ROE (%) only.
CORT' s 10-Year ROE (%) Range
Min: -8507.59  Med: -117.64 Max: -55.4
Current: -596.12
-8507.59
-55.4
ROA (%) -51.29
CORT's ROA (%) is ranked lower than
70% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. CORT: -51.29 )
Ranked among companies with meaningful ROA (%) only.
CORT' s 10-Year ROA (%) Range
Min: -124.18  Med: -80.36 Max: -51.57
Current: -51.29
-124.18
-51.57
ROC (Joel Greenblatt) (%) -1489.93
CORT's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. CORT: -1489.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CORT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -370585.71  Med: -69112.91 Max: -2412.14
Current: -1489.93
-370585.71
-2412.14
EBITDA Growth (3Y)(%) -11.50
CORT's EBITDA Growth (3Y)(%) is ranked lower than
61% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. CORT: -11.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CORT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -11.50 Max: 2.6
Current: -11.5
0
2.6
EPS Growth (3Y)(%) -7.40
CORT's EPS Growth (3Y)(%) is ranked higher than
50% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. CORT: -7.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CORT' s 10-Year EPS Growth (3Y)(%) Range
Min: -31.3  Med: -7.40 Max: 6.6
Current: -7.4
-31.3
6.6
» CORT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CORT Guru Trades in Q3 2013

Steven Cohen 500,000 sh (+11.11%)
First Eagle Investment 2,496,078 sh (-1.61%)
» More
Q4 2013

CORT Guru Trades in Q4 2013

Steven Cohen Sold Out
First Eagle Investment 991,978 sh (-60.26%)
» More
Q1 2014

CORT Guru Trades in Q1 2014

Steven Cohen 14,329 sh (New)
First Eagle Investment Sold Out
» More
Q1 2015

CORT Guru Trades in Q1 2015

Jim Simons 55,400 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CORT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 49.80
CORT's P/B is ranked lower than
98% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CORT: 49.80 )
Ranked among companies with meaningful P/B only.
CORT' s 10-Year P/B Range
Min: 1.26  Med: 5.27 Max: 97.67
Current: 49.8
1.26
97.67
P/S 15.56
CORT's P/S is ranked lower than
55% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. CORT: 15.56 )
Ranked among companies with meaningful P/S only.
CORT' s 10-Year P/S Range
Min: 10.69  Med: 154.00 Max: 615
Current: 15.56
10.69
615
Current Ratio 2.85
CORT's Current Ratio is ranked lower than
64% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. CORT: 2.85 )
Ranked among companies with meaningful Current Ratio only.
CORT' s 10-Year Current Ratio Range
Min: 2.22  Med: 7.91 Max: 37.77
Current: 2.85
2.22
37.77
Quick Ratio 2.76
CORT's Quick Ratio is ranked lower than
62% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CORT: 2.76 )
Ranked among companies with meaningful Quick Ratio only.
CORT' s 10-Year Quick Ratio Range
Min: 2.14  Med: 7.91 Max: 37.77
Current: 2.76
2.14
37.77
Days Inventory 418.92
CORT's Days Inventory is ranked lower than
92% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. CORT: 418.92 )
Ranked among companies with meaningful Days Inventory only.
CORT' s 10-Year Days Inventory Range
Min: 476.53  Med: 1710.69 Max: 2487.36
Current: 418.92
476.53
2487.36
Days Sales Outstanding 48.68
CORT's Days Sales Outstanding is ranked higher than
64% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. CORT: 48.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
CORT' s 10-Year Days Sales Outstanding Range
Min: 45.83  Med: 50.33 Max: 61.48
Current: 48.68
45.83
61.48

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 82.00
CORT's Price/Net Current Asset Value is ranked lower than
96% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. CORT: 82.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CORT' s 10-Year Price/Net Current Asset Value Range
Min: 2.43  Med: 5.88 Max: 93.33
Current: 82
2.43
93.33
Price/Tangible Book 49.20
CORT's Price/Tangible Book is ranked lower than
97% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. CORT: 49.20 )
Ranked among companies with meaningful Price/Tangible Book only.
CORT' s 10-Year Price/Tangible Book Range
Min: 2.31  Med: 5.50 Max: 93.33
Current: 49.2
2.31
93.33
Price/Median PS Value 0.10
CORT's Price/Median PS Value is ranked higher than
98% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. CORT: 0.10 )
Ranked among companies with meaningful Price/Median PS Value only.
CORT' s 10-Year Price/Median PS Value Range
Min: 0.07  Med: 0.46 Max: 3.37
Current: 0.1
0.07
3.37
Earnings Yield (Greenblatt) (%) -3.48
CORT's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CORT: -3.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CORT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -11  Med: 3588.90 Max: 3588.9
Current: -3.48
-11
3588.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HTD.Germany,
Corcept Therapeutics Inc was incorporated in the State of Delaware on May 13, 1998. The Company is a pharmaceutical Company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric and oncologic disorders. Company focuses on disorders associated with the steroid hormone cortisol. The company focuses on commercializing Korlym 300 mg Tablet, a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is also conducting a Phase III clinical study for mifepristone, the active ingredient in Korlym, for the treatment of psychotic depression; and developing CORT 108297, a novel glucocorticoid receptor II antagonist in Phase 1b/2a clinical trial. The Company has research and development agreement with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone.
» More Articles for CORT

Headlines

Articles On GuruFocus.com
Two Stocks for the Value Investor and GAARP Enthusiast Jun 07 2014 
Corcept Therapeutics Inc. Reports Operating Results (10-K/A) Aug 19 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 16 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Nov 12 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 11 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) May 13 2009 

More From Other Websites
Cortendo Announces Plans to Conduct Registered Initial Public Offering of Its Common Shares Jul 20 2015
CORCEPT THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 07 2015
Cortendo Provides 2015 Half-Year Update on Corporate Progress Jul 02 2015
Resolutions by the Annual General Meeting in Cortendo AB (publ) Jun 25 2015
3 Pharmaceutical Stocks to Sell Now Jun 25 2015
Corcept Therapeutics Appoints Daniel Swisher to Board of Directors Jun 22 2015
CORCEPT THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 22 2015
Corcept Therapeutics Appoints Daniel Swisher to Board of Directors Jun 22 2015
Cortendo Announces Notice of Annual General Meeting May 22 2015
CORCEPT THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 21 2015
Notification of Trade May 19 2015
Corcept Therapeutics' Korlym Positive in Breast Cancer Study - Analyst Blog May 15 2015
CORCEPT THERAPEUTICS INC Financials May 15 2015
Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related... May 15 2015
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14 2015
Corcept Therapeutics Announces Poster Presentations on Mifepristone for the Treatment of Patients... May 14 2015
Corcept Therapeutics Announces Poster Presentations on Mifepristone for the Treatment of Patients... May 14 2015
Corcept Therapeutics' Mifepristone Combined with Eribulin to Improve Antitumor Activity in Patients... May 14 2015
Corcept Therapeutics' Mifepristone Combined With Eribulin to Improve Antitumor Activity in Patients... May 13 2015
10-Q for Corcept Therapeutics, Inc. May 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK